한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제40권4호
  • /
  • Pages.276-282
  • /
  • 2023
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Treatment with a Combination of Prednisolone and Mycophenolate Mofetil for Dogs with Immune-Mediated Polyarthritis

  • Jung-Il Kim (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Jin-Young Kim (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Jeong-Yeol Bae (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Guk Il Joung (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Joong-Hyun Song (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2023.04.10
  • 심사 : 2023.07.16
  • 발행 : 2023.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Immune-mediated polyarthritis (IMPA) is an inflammatory, noninfectious disease that affects two or more joints in dogs. Immunosuppressive doses of prednisolone are considered the initial treatment choice for dogs with IMPA. However, few reports have described the combination of mycophenolate mofetil and prednisolone for treating dogs with IMPA. In this report, we described the cases of three dogs treated with a combination of mycophenolate mofetil and prednisolone. The clinical signs were alleviated in all cases, and C-reactive protein levels were reduced after treatment. Our results show that combination therapy of mycophenolate mofetil and prednisolone is effective in managing IMPA. However, careful monitoring of the potential adverse effects, including sporadic infections and metabolic diseases, is necessary. In addition, screening tests and appropriate treatments are necessary for proteinuria, a common complication in dogs with IMPA.

키워드

과제정보

This study was supported by the National Research Foundation of Korea and funded by a grant from the Korean Government (NRF-2022R1G1A10036821131482092640101).

참고문헌

  1. Barker L, McManus S, Adamantos S, Black V. Point prevalence and clinical course of proteinuria in dogs with idiopathic non-erosive immune-mediated polyarthritis. J Small Anim Pract 2022; 63: 619-623.  https://doi.org/10.1111/jsap.13503
  2. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, Rodriguez-Rodriguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci 2013; 14: 8638-8683.  https://doi.org/10.3390/ijms14048638
  3. Clements DN, Gear RN, Tattersall J, Carmichael S, Bennett D. Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002). J Am Vet Med Assoc 2004; 224: 1323-1327.  https://doi.org/10.2460/javma.2004.224.1323
  4. Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). J Am Vet Med Assoc 2010; 236: 312-318.  https://doi.org/10.2460/javma.236.3.312
  5. Eom NY, Lee HC, Jang HM, Jung DI. A case of treatment of idiopathic immune-mediated polyarthritis in a dog. J Vet Clin 2015; 32: 366-369.  https://doi.org/10.17555/jvc.2015.08.32.4.366
  6. Ettinger SJ, Feldman EC, Cote E. Textbook of veterinary internal medicine. St. Louis: Elsevier. 2017: 72-75. 
  7. Ettinger SJ, Feldman EC, Cote E. Textbook of veterinary internal medicine. St. Louis: Elsevier. 2017: 861-865. 
  8. Fukushima K, Lappin M, Legare M, Veir J. A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune-mediated disease. J Vet Intern Med 2021; 35: 2215-2221. Erratum in: J Vet Intern Med 2022; 36: 1844. 
  9. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997; 159: 574-581.  https://doi.org/10.4049/jimmunol.159.2.574
  10. Harley L, Langston C. Proteinuria in dogs and cats. Can Vet J 2012; 53: 631-638. 
  11. High EJ, Olivry T. The prevalence of bacterial infections during cyclosporine therapy in dogs: a critically appraised topic. Can Vet J 2020; 61: 1283-1289. 
  12. Johnson KC, Mackin A. Canine immune-mediated polyarthritis: part 2: diagnosis and treatment. J Am Anim Hosp Assoc 2012; 48: 71-82.  https://doi.org/10.5326/JAAHA-MS-5756
  13. Klotsman M, Sathyan G, Anderson WH, Garden OA, Shivanand P. Mycophenolic acid in patients with immune-mediated inflammatory diseases: from humans to dogs. J Vet Pharmacol Ther 2019; 42: 127-138.  https://doi.org/10.1111/jvp.12731
  14. Martinez CR, Santangelo KS. Preanalytical considerations for joint fluid evaluation. Vet Clin North Am Small Anim Pract 2017; 47: 111-122.  https://doi.org/10.1016/j.cvsm.2016.07.007
  15. McAtee BB, Cummings KJ, Cook AK, Lidbury JA, Heseltine JC, Willard MD. Opportunistic invasive cutaneous fungal infections associated with administration of cyclosporine to dogs with immune-mediated disease. J Vet Intern Med 2017; 31: 1724-1729.  https://doi.org/10.1111/jvim.14824
  16. Nelson RW. Canine diabetes mellitus. In: Feldman EC, Nelson RW, Reusch CE, Scott-Moncrieff JCR, editors. Canine and feline endocrinology. 4th ed. St. Louis: W.B. Saunders. 2015: 213-257. 
  17. Nelson RW, Couto CG. Common immune-mediated diseases. In: Nelson RW, Couto CG, editors. Small animal internal medicine. 6th ed. Philadelphia: Elsevier - Health Sciences Division. 2019: 1245-1247. 
  18. Nelson RW, Couto CG. Treatment of primary immune-mediated diseases. In: Nelson RW, Couto CG, editors. Small animal internal medicine. 6th ed. Philadelphia: Elsevier - Health Sciences Division. 2019: 1220-1229. 
  19. Ohno K, Yokoyama Y, Nakashima K, Setoguchi A, Fujino Y, Tsujimoto H. C-reactive protein concentration in canine idiopathic polyarthritis. J Vet Med Sci 2006; 68: 1275-1279.  https://doi.org/10.1292/jvms.68.1275
  20. Peace AC, Kumar S, Wills R, Mackin A, Hoh CM, Archer T. Pharmacodynamic evaluation of the effects of oral melatonin on expression of the T-cell cytokines interleukin-2 and interferon gamma in the dog. J Vet Pharmacol Ther 2019; 42: 278-284.  https://doi.org/10.1111/jvp.12749
  21. Plumb DC. Plumb's veterinary drug handbook: desk. Hoboken: John Wiley & Sons. 2018. 
  22. Rhoades AC, Vernau W, Kass PH, Herrera MA, Sykes JE. Comparison of the efficacy of prednisone and cyclosporine for treatment of dogs with primary immune-mediated polyarthritis. J Am Vet Med Assoc 2016; 248: 395-404.  https://doi.org/10.2460/javma.248.4.395
  23. Rodriguez MI, Escames G, Lopez LC, Lopez A, Garcia JA, Ortiz F, et al. Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice. J Pineal Res 2007; 42: 272-279.  https://doi.org/10.1111/j.1600-079X.2006.00416.x
  24. Stull JW, Evason M, Carr AP, Waldner C. Canine immune-mediated polyarthritis: clinical and laboratory findings in 83 cases in western Canada (1991-2001). Can Vet J 2008; 49: 1195-1203. 
  25. Viviano KR. Update on immununosuppressive therapies for dogs and cats. Vet Clin North Am Small Anim Pract 2013; 43: 1149-1170.  https://doi.org/10.1016/j.cvsm.2013.04.009
  26. Waters CB, Adams LG, Scott-Moncrieff JC, DeNicola DB, Snyder PW, White MR, et al. Effects of glucocorticoid therapy on urine protein-to-creatinine ratios and renal morphology in dogs. J Vet Intern Med 1997; 11: 172-177. https://doi.org/10.1111/j.1939-1676.1997.tb00086.x